Mosaic ImmunoEngineering (CPMV) Total Liabilities (2011 - 2026)
Mosaic ImmunoEngineering (CPMV) posted quarterly Total Liabilities of $7.7 million for Q1 2026, up 8.4% year-over-year from $7.1 million in Q1 2025, and up 2.21% quarter-over-quarter from $7.5 million in Q4 2025.
Mosaic ImmunoEngineering (CPMV) Total Liabilities (2011 - 2026) Analysis & Trends
Mosaic ImmunoEngineering's Total Liabilities history runs 16 years deep, the most recent figure standing at $7.7 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 8.4% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $7.7 million (up 8.4% YoY), while the FY2025 annual figure was $7.5 million, up 8.17% from the prior year.
- Total Liabilities for Q1 2026 stood at $7.7 million, up from $7.5 million in the prior quarter.
- The five-year high for Total Liabilities was $7.7 million in Q1 2026, with the low at $3.8 million in Q1 2022.
- The 5-year median for Total Liabilities is $6.2 million (2024), against an average of $6.1 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 213.01% in 2022, then increased 8.17% in 2025.
- Mosaic ImmunoEngineering's Total Liabilities stood at $5.1 million in 2022, then advanced by 17.58% to $6.1 million in 2023, then grew by 14.53% to $6.9 million in 2024, then increased by 8.17% to $7.5 million in 2025, then increased by 2.21% to $7.7 million in 2026.
- Business Quant data shows CPMV's Total Liabilities at $7.7 million in Q1 2026, $7.5 million in Q4 2025, and $7.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | 7.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.66 Mn |
| Dec 31, 2025 | 7.50 Mn |
| Sep 30, 2025 | 7.36 Mn |
| Jun 30, 2025 | 7.20 Mn |
| Mar 31, 2025 | 7.07 Mn |
| Dec 31, 2024 | 6.93 Mn |
| Sep 30, 2024 | 6.68 Mn |
| Jun 30, 2024 | 6.46 Mn |
| Mar 31, 2024 | 6.23 Mn |
| Dec 31, 2023 | 6.05 Mn |
| Sep 30, 2023 | 5.87 Mn |
| Jun 30, 2023 | 5.62 Mn |
| Mar 31, 2023 | 5.43 Mn |
| Dec 31, 2022 | 5.15 Mn |
| Sep 30, 2022 | 4.79 Mn |
| Jun 30, 2022 | 4.48 Mn |
| Mar 31, 2022 | 3.83 Mn |
| Dec 31, 2021 | 3.07 Mn |
| Sep 30, 2021 | 2.65 Mn |
| Jun 30, 2021 | 2.12 Mn |